{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-055102","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.150166+00:00","generated_at":"2026-06-16T02:46:56.808238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CytoSorbents Q1 product sales flat at $7.9M; STAR-T enrollment on track; cash burn cut to $3.1M","bullets":["Q1 product sales $7.9M flat YoY; core constant currency sales +8.3% to $8.3M; total revenue $9.4M (+9%).","Product gross margin fell to 68% from 80% due to new manufacturing facility start-up costs.","STAR-T trial enrollment at 80 patients (March milestone); expects enrollment completion summer 2023, topline data by year-end.","Cash burn reduced to $3.1M from $9.1M YoY; cash $20.7M (incl $1.7M restricted); expects no material capex.","Chairman Al Kraus retiring June 2023; Michael Bator to succeed as Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-055102","json":"https://secwatch.observer/filing/0001104659-23-055102.json","markdown":"https://secwatch.observer/filing/0001104659-23-055102.md","text":"https://secwatch.observer/filing/0001104659-23-055102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923055102/0001104659-23-055102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923055102/tm2314358d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:46:56.808238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"638bff3b7a3c454a20fb4f8d200ebbd4e871be0f","claim":"Cytosorbents Corp reported First Quarter 2023 results: revenue Total revenue, including product sales and grant income, for Q1 2023 was $9.4 million.","evidence_excerpt":"Today reported unaudited financial and operating results for the quarter ended March 31, 2023. First Quarter 2023 Financial Results · Total revenue, including product sales and grant income, for Q1 2023 was $9.4 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923055102/0001104659-23-055102-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2023"},{"label":"Revenue","value":"Total revenue, including product sales and grant income, for Q1 2023 was $9.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}